Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma
Authors:
- Suzanne I.M. NeppelenbroekSNSuzanne I.M. Neppelenbroek
- Yvonne M. GeurtsYvonne M. Geurts
- Berthe M.P. AlemanBerthe M.P. Aleman
- Pieternella J. LugtenburgPieternella J. Lugtenburg
- Bastiaan D.P. TaBTBastiaan D.P. Ta
- Wouter J. PlattelWouter J. Plattel
- Josée M. ZijlstraJosée M. Zijlstra
- Richard W.M. van der MaazenRMRichard W.M. van der Maazen
- Marten R. NijzielMarten R. Nijziel
Open Access
- 1 June 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (16) , 1903-1913
Abstract
PURPOSE: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages. METHODS: We assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses. RESULTS: After a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m2 doxorubicin ( Ptrend = .004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR]age , 1.5 [95% CI, 0.9 to 2.6]; HRage ≥21 years, 1.3 [95% CI, 0.9 to 1.9) or chest RT (HRwithout mantle/axillary field RT, 1.9 [95% CI, 1.06 to 3.3]; HRwith mantle/axillary field RT, 1.2 [95% CI, 0.8 to 1.8]). CONCLUSION: This study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.Keywords
This publication has 48 references indexed in Scilit:
- Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studiesThe Lancet Oncology, 2012
- Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort StudyJournal of Clinical Oncology, 2012
- Radiation Dose and Breast Cancer Risk in the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2009
- Malignant mesothelioma after radiation treatment for Hodgkin lymphomaBlood, 2009
- Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's DiseaseNew England Journal of Medicine, 2007
- Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study GroupJournal of Clinical Oncology, 2003
- Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood, 2002
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPCancer, 1975
- Transforming Potential of the Anticancer Drug AdriamycinScience, 1975